ISAL 2023 | Implementing MRD in clinical practice for patients with intermediate-risk AML
Jacqueline Cloos, PhD, Amsterdam UMC, Amsterdam, The Netherlands, highlights challenges with implementing measurable residual disease (MRD) in clinical practice for acute myeloid leukemia (AML). Prof. Cloos then comments on the possibility of using MRD to guide treatment decisions in patients with intermediate-risk disease, which has been explored in the HOVON-SAKK-132 trial (EudraCT 2013-002843-26). This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Disclosure (institute) received research funding from Takeda, DC-one, Genentech, Janssen, Novartis, Merus and royalties from Navigate and BD Biosciences.
